pdufa.bio
CalendarDecisionsApprovals/yrTrial oddsLearnResearchMethodology
Home › PDUFA Calendar › PRAX

PRAX PDUFA Date: Relutrigine (PRAX-562)

FDA decision (PDUFA) target 2026-09-27 · Praxis Precision Medicines Inc. · Developmental epileptic encephalopathies (DEEs)

PRAX run-up into the PDUFA (last ~120 days)

$357.13$240.66
Price path to 2026-06-19. Green = local high, red = low/sell-off. Historical price action, not a forecast.

Key facts

FDA PDUFA target date2026-09-27
Drug / candidateRelutrigine (PRAX-562)
IndicationDevelopmental epileptic encephalopathies (DEEs)
CompanyPraxis Precision Medicines Inc.
Market-cap tierMid
Cohort decision-day move (history)±2% median
ClinicalTrials.govNCT05818553 · active

New to FDA decisions? Read what a PDUFA date is and how often the FDA approves drugs.

Track this live → price, options (expected move & IV) and the full dashboard
Opens the pdufa.bio app (private beta)

FAQ

When is the PRAX PDUFA date?
The FDA PDUFA target date for PRAX (Praxis Precision Medicines Inc.) is 2026-09-27 for Relutrigine (PRAX-562). Dates are company/FDA-sourced and can slip — verify against primary filings.
What is PRAX's drug Relutrigine (PRAX-562)?
Relutrigine (PRAX-562) is Praxis Precision Medicines Inc.'s candidate under FDA review for Developmental epileptic encephalopathies (DEEs).
What typically happens to a mid-cap stock into a PDUFA date?
Historically, mid-cap names had a median decision-day move around ±2% (694-PDUFA cohort, 2024–26). This is historical context by market-cap tier, not a prediction for this drug.